ReviewDrug design, development and therapy2026
Multi-Technology Empowers Dissolving Microneedles: A Novel Strategy in Rheumatoid Arthritis.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a systemic autoimmune disease associated with chronic inflammation. Current clinical management is confronted with multiple challenges, such as suboptimal drug bioavailability, insufficient joint targeting, and poor patient compliance, which critically limit therapeutic efficacy. Dissolving microneedles (DMNs) can overcome the limitations of traditional treatments through minimally invasive transdermal delivery, improve efficacy and reduce toxicity and side effects, offering an innovative solution for RA treatment. This article reviews the advantages of DMNs for RA, analyzes the advantages and limitations of their preparation methods, the physicochemical properties of DMN matrix materials and the application progress in RA treatment. The synergistic strategies of DMNs with nano-delivery systems, cell membrane bionics, stimulus response delivery systems and phototherapy are further discussed. This multi-technology integration solution solves the problems of poor targeting, low bioavailability, high toxic side effects, and poor patient compliance in RA treatment through the advantages of physical targeting, intelligent controlled release and portable drug delivery. Finally, combined with the patent landscape and clinical research progress, the existing challenges and future development prospects of DMNs in RA treatment are analyzed, hoping to provide theoretical basis and technical breakthrough direction for RA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.